Ignite Creation Date:
2025-12-24 @ 10:48 PM
Ignite Modification Date:
2025-12-25 @ 8:17 PM
Study NCT ID:
NCT04353869
Status:
COMPLETED
Last Update Posted:
2025-03-05
First Post:
2020-04-16
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Targeting Glutamine Metabolism to Prevent Diabetic Cardiovascular Complications
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}]}}, 'protocolSection': {'designModule': {'bioSpec': {'retention': 'SAMPLES_WITH_DNA', 'description': 'Venous blood, Urine'}, 'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'CROSS_SECTIONAL', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 995}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2020-11-16', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-03', 'completionDateStruct': {'date': '2024-01-10', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-02-28', 'studyFirstSubmitDate': '2020-04-16', 'studyFirstSubmitQcDate': '2020-04-16', 'lastUpdatePostDateStruct': {'date': '2025-03-05', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2020-04-21', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-01-10', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Compare the plasma concentrations of glutamine in patients with various levels of cardiovascular (CV) risk.', 'timeFrame': 'DAY 1', 'description': 'plasma concentration of glutamine in each subject.'}], 'secondaryOutcomes': [{'measure': 'Study glutamine metabolism in patients with various levels of CV risk', 'timeFrame': 'DAY 1', 'description': 'plasma concentration of glutamate in each treatment group'}, {'measure': 'Study glutamine metabolism in patients with various levels of CV risk', 'timeFrame': 'DAY1', 'description': 'plasma concentration of a-ketoglutarate, fumarate, and succinate in each treatment group'}, {'measure': 'Study glutamine metabolism in patients with various levels of CV risk', 'timeFrame': 'DAY 1', 'description': 'monocyte cytoplasmic concentration of a-ketoglutarate, fumarate and succinate in each treatment group'}, {'measure': 'study the inflammatory status in patients with various levels of CV risk', 'timeFrame': 'DAY 1', 'description': 'plasma concentration of VEGF (Vascular endothelial growth factor) in each treatment group'}, {'measure': 'study the inflammatory status in patients with various levels of CV risk', 'timeFrame': 'DAY 1', 'description': 'plasma concentration of the proinflammatory cytokines IL-1, IL-6, IL-8 (interleukin) and TNF-a (Tumor Necrosis Factor alpha)'}, {'measure': 'study the inflammatory status in patients with various levels of CV risk', 'timeFrame': 'DAY 1', 'description': 'blood concentration of circulating PBMCs (peripheral blood mononuclear cell)'}, {'measure': 'study the monocyte activation status in patients with various levels of CV risk', 'timeFrame': 'DAY 1', 'description': 'frequency of monocyte subsets (CD14++CD16+, CD14++CD16++, CD14+CD16++)'}, {'measure': 'characterize the transcriptomic program through modification gene expression and epigenetic changes related to KDM6B (Lysine Demethylase 6B) and TET2 (Ten-eleven-translocation 2) activity in blood monocytes from patients with various levels of CV risk', 'timeFrame': 'DAY 1', 'description': 'Number of transcript for each gene'}, {'measure': 'characterize the transcriptomic program through modification gene expression and epigenetic changes related to KDM6B and TET2 activity in blood monocytes from patients with various levels of CV risk', 'timeFrame': 'DAY 1', 'description': 'Number of methylated gene loci and their proportion of methylation'}, {'measure': 'characterize the transcriptomic program through modification gene expression and epigenetic changes related to KDM6B and TET2 activity in blood monocytes from patients with various levels of CV risk', 'timeFrame': 'DAY 1', 'description': 'Frequency and level of histone H3K27me (Methylation of lysine 27 on histone H3) methylation'}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Diabetes', 'Cardiovascular complications', 'Glutamine metabolism'], 'conditions': ['Glutamine', 'Diabetic', 'Cardiovascular Complications']}, 'referencesModule': {'references': [{'pmid': '38152893', 'type': 'DERIVED', 'citation': 'Julla JB, Girard D, Diedisheim M, Saulnier PJ, Tran Vuong B, Bleriot C, Carcarino E, De Keizer J, Orliaguet L, Nemazanyy I, Potier C, Khider K, Tonui DC, Ejlalmanesh T, Ballaire R, Mambu Mambueni H, Germain S, Gaborit B, Vidal-Trecan T, Riveline JP, Garchon HJ, Fenaille F, Lemoine S, Carlier A, Castelli F, Potier L, Masson D, Roussel R, Vandiedonck C, Hadjadj S, Alzaid F, Gautier JF, Venteclef N. Blood Monocyte Phenotype Is A Marker of Cardiovascular Risk in Type 2 Diabetes. Circ Res. 2024 Jan 19;134(2):189-202. doi: 10.1161/CIRCRESAHA.123.322757. Epub 2023 Dec 28.'}]}, 'descriptionModule': {'briefSummary': 'Experimental data suggest that glutamine catabolism in involved in the activation of macrophages by generating TCA(Tricarboxylic acid) intermediates that promote the pro-inflammatory polarization of macrophages. The project investigates the possible link between glutaminolysis, monocytes polarization and diabetes related cardiovascular complications in humans', 'detailedDescription': "The aim of the study is to investigate the role of glutamine metabolism in the pro-inflammatory activation of macrophages in diabetes and related cardiovascular complications.\n\nThe study focuses on 3 adult patients' population with different diabetic status and level of cardiovascular risk:\n\n* Patients with uncomplicated type 1 or type 2 diabetes and low cardiovascular risk\n* Patients with uncomplicated type 1 or type 2 diabetes and high cardiovascular risk\n* Patients with complicated type 1 or type 2 diabetes\n\nParticipants (n=975) will be recruited at clinical sites, in the diabetes and cardiology departments (APHP, Bichat - Claude-Bernard Hospital and APHP, Lariboisière Hospital), over a 2-year period.\n\nThe study will consist in a single visit. During a scheduled hospitalization or consultation as part of the follow-up of their diabetes or as part of the follow-up of their cardiological problems, clinical data will be collected as well as additional blood and urine samples for analyses and biobanking. There will be no other intervention specific to the study."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'samplingMethod': 'PROBABILITY_SAMPLE', 'studyPopulation': 'Adult Type 1 and 2 diabetic patients and non-diabetic subjects with various levels of cardiovascular risk', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion criteria General inclusion criteria applying to the five populations are the following:\n\n* Age above 18 years\n* BMI between 25 and 40 kg/m²\n\nInclusion criteria according to study group are listed below.\n\nGroup 1: Patients with uncomplicated diabetes and low cardiovascular risk, additional inclusion criteria are:\n\n* 5 or more years of diabetes\n* 6% \\< HbA1c \\< 10%\n* no history of cardiovascular event, diabetic microvascular complications (kidney function normal and albuminuria/creatininuria \\< 30 mg/g)\n* Coronary artery calcium score \\< 100 (assessment \\< 12 months)\n\nGroup 2: Patients with uncomplicated diabetes and high cardiovascular risk, additional inclusion criteria are:\n\n* 5 or more years of diabetes\n* 6% \\< HbA1c \\< 10%\n* no history of cardiovascular eventand diabetic nephropathy no more than stage 2 (i.e. GFR ≥ 60 ml/min by MDRD or CKD-EPI formula and albuminuria/creatininuria ≤ 30 mg/g)\n* Coronary artery calcium score \\> 400 (assessment \\< 12 months)\n\nGroup 3: Patients with complicated diabetes, additional inclusion criteria are:\n\n* 5 or more years of diabetes\n* 6% \\< HbA1c \\< 10%\n* A history of cardiovascular event (myocardial infarction, stroke, peripheral vascular disease, or angioplasty) at least 3 months ago\n\nExclusion Criteria:\n\n* Solid organ or bone marrow transplant patient\n* Pregnant or breastfeeding woman\n* Absence of free and informed consent\n* Non-affiliation to a social security regimen or CMU (universal health coverage)\n* Subject deprived of freedom, subject under a legal protective measure'}, 'identificationModule': {'nctId': 'NCT04353869', 'acronym': 'GLUTADIAB', 'briefTitle': 'Targeting Glutamine Metabolism to Prevent Diabetic Cardiovascular Complications', 'organization': {'class': 'OTHER', 'fullName': 'Assistance Publique - Hôpitaux de Paris'}, 'officialTitle': 'Targeting Glutamine Metabolism to Prevent Diabetic Cardiovascular Complications', 'orgStudyIdInfo': {'id': 'GLUTADIAB'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Group 1', 'description': 'Patients with uncomplicated diabetes and low cardiovascular risk\n\nDuring a scheduled hospitalization or consultation as part of the follow-up of their diabetes additions of biological samples, which include:\n\nA unique venous blood sampling of 9 tubes: 4 x 7 mL EDTA (Éthylènediaminetétraacétique) tubes + 3 x 5 mL EDTA tubes + 2 x 4 mL no additive tubes (total: 51 mL) at a single time during the study and collection of 2 monovettes of 1.6 ml urine (total: 3.2 mL).', 'interventionNames': ['Biological: Bio collection']}, {'label': 'Group 2', 'description': 'Patients with uncomplicated diabetes and high cardiovascular risk\n\nDuring a scheduled hospitalization or consultation as part of the follow-up of their diabetes additions of biological samples, which include:\n\nA unique venous blood sampling of 9 tubes: 4 x 7 mL EDTA tubes + 3 x 5 mL EDTA tubes + 2 x 4 mL no additive tubes (total: 51 mL) at a single time during the study and collection of 2 monovettes of 1.6 ml urine (total: 3.2 mL).', 'interventionNames': ['Biological: Bio collection']}, {'label': 'Group 3', 'description': 'Patients with complicated diabetes\n\nDuring a scheduled hospitalization or consultation as part of the follow-up of their diabetes additions of biological samples, which include:\n\nA unique venous blood sampling of 9 tubes: 4 x 7 mL EDTA tubes + 3 x 5 mL EDTA tubes + 2 x 4 mL no additive tubes (total: 51 mL) at a single time during the study and collection of 2 monovettes of 1.6 ml urine (total: 3.2 mL).', 'interventionNames': ['Biological: Bio collection']}], 'interventions': [{'name': 'Bio collection', 'type': 'BIOLOGICAL', 'description': 'venous blood sampling and collection of urine', 'armGroupLabels': ['Group 1', 'Group 2', 'Group 3']}]}, 'contactsLocationsModule': {'locations': [{'zip': '75010', 'city': 'Paris', 'state': 'France', 'country': 'France', 'facility': 'Diabétologie - Hôpital Lariboisière', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '75018', 'city': 'Paris', 'state': 'France', 'country': 'France', 'facility': 'Diabetologie Bichat', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Assistance Publique - Hôpitaux de Paris', 'class': 'OTHER'}, 'collaborators': [{'name': 'National Research Agency, France', 'class': 'OTHER'}], 'responsibleParty': {'type': 'SPONSOR'}}}}